CBIO CRESCENT BIOPHARMA, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1253689 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-58.7%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-1,216.6%
Net margin-727.6%
FCF margin-549.5%
EBITDA margin-1,214.9%
Returns
ROE-55.8%
ROA-49.9%
ROIC (approx.)—
Asset turnover0.07x
Leverage & solvency
Liabilities / assets8.4%
Debt / equity0.00x
Current ratio12.57x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.75x
Accruals ratio-12.4%
Payout ratio—
Capex / revenue2.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $10.84M | — | $10,000 | $75,000 | $1.16M |
| R&D expense | $138.09M | $14.26M | $20.07M | $28.39M | $47.49M |
| SG&A expense | $25.39M | $18.25M | $19.21M | $19.09M | $17.12M |
| Operating income | -$152.63M | -$40.04M | -$39.28M | -$47.40M | -$63.45M |
| Interest expense | $2.19M | — | — | — | — |
| Pretax income | -$151.94M | — | — | — | — |
| Income tax | $2.00M | — | — | — | — |
| Net income | -$153.94M | -$37.88M | -$36.90M | -$46.69M | -$63.43M |
| EBITDA | -$152.55M | -$40.00M | -$39.12M | -$47.20M | -$63.18M |
| EPS (basic) | — | -0.59 | -0.58 | -0.89 | -1.23 |
| EPS (diluted) | — | -0.59 | -0.58 | -0.89 | -1.23 |
| Weighted avg. shares (diluted) | — | 64.48M | 63.34M | 52.53M | 51.45M |
| Balance sheet | |||||
| Cash & equivalents | $213.19M | $34.77M | $41.79M | $47.87M | $90.25M |
| Receivables | $18.00M | $0 | — | — | — |
| Current assets | $236.66M | $34.80M | $43.79M | $50.71M | $90.79M |
| PP&E, net | $846,000 | $0 | — | $242,390 | $368,842 |
| Total assets | $240.29M | $35.62M | $45.32M | $51.81M | $94.35M |
| Current liabilities | $36.07M | $9.61M | $6.84M | $8.88M | $11.82M |
| Total liabilities | $37.28M | $47.10M | $6.90M | $8.88M | $12.74M |
| Shareholders' equity | $203.01M | -$15.48M | $38.41M | $42.93M | $81.60M |
| Shares outstanding | 27.56M | 1.02M | 64.39M | 54.38M | 52.31M |
| Cash flow statement | |||||
| Operating cash flow | -$71.53M | -$31.10M | -$34.88M | -$46.46M | -$57.49M |
| Capital expenditure | $919,000 | $9,972 | $21,394 | $84,191 | $14,943 |
| Free cash flow | -$72.45M | -$31.11M | -$34.90M | -$46.54M | -$57.50M |
| Investing cash flow | -$72.92M | $20,028 | -$21,394 | -$84,191 | -$14,943 |
| Financing cash flow | $322.98M | $5,398 | $28.82M | $4.16M | $10.72M |
| Depreciation & amortization | $84,000 | $35,174 | $153,301 | $207,145 | $264,600 |
| Stock-based compensation | $13.30M | $4.70M | $3.52M | $3.86M | $6.09M |
Free plan shows the latest 5 periods; Pro shows all 14 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.